This podcast features a detailed discussion on the recent ODAC meeting, focusing on the evaluation of capivasertib, an AKT inhibitor in metastatic hormone-sensitive prostate cancer. Experts analyze trial data, benefit-risk considerations, biomarker challenges, and regulatory perspectives.